Estrella Immunopharma, Inc.
For the period ended Mar 31, 2026. Filed May 18, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 18, 2026
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
| As of March 31, 2026 | As of December 31, 2025 | |
|---|---|---|
| (Unaudited) | ||
| Current Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,927,404 | $1,384,302 |
| Prepaid expenses and other receivables | 229,794 | 292,673 |
| Total current assets | 2,157,198 | 1,676,975 |
| Other Assets | ||
| Prepaid expenses, related party, non-current | 1,500,000 | 1,500,000 |
| Total Assets | $3,657,198 | $3,176,975 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable - related party | $14,947 | $554,781 |
| Other payables and accrued liabilities | 179,082 | 238,414 |
| Accrued liability - related party | 8,268,333 | 12,393,333 |
| Derivative liabilities | 465,132 | 356,505 |
| Total current liabilities | 8,927,494 | 13,543,033 |
| Total Liabilities | 8,927,494 | 13,543,033 |
| Commitments and Contingencies (Note 4) | ||
| Preferred Stock | ||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | - | - |
| Stockholders’ Deficit: | ||
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 43,180,509 and 38,486,219 shares issued as of March 31, 2026 and December 31, 2025, respectively | 4,318 | 3,849 |
| Additional paid-in capital | 34,606,644 | 27,219,287 |
| Accumulated deficit | (39,282,879) | (36,990,815) |
| Treasury stock, at cost 515,281 shares as of March 31, 2026 and December 31, 2025 | (598,379) | (598,379) |
| Total Stockholders’ Deficit | (5,270,296) | (10,366,058) |
| Total Liabilities and Stockholders’ Deficit | $3,657,198 | $3,176,975 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.